Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma

Between June 2003 and November 2004, we collected mobilized peripheral blood units from 29 patients with non-Hodgkin's lymphoma and multiple myeloma for autologous peripheral blood stem cell transplantation. They received granulocyte colony-stimulating factor (G-CSF) (16 micro g/kg/day) for a t...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2006-05, Vol.85 (5), p.308-314
Main Authors: Vela-Ojeda, J, García-Ruiz Esparza, M A, Reyes-Maldonado, E, Jiménez-Zamudio, L, García-Latorre, E, Moreno-Lafont, M, Estrada-García, I, Mayani, H, Montiel-Cervantes, L, Tripp-Villanueva, F, Ayala-Sánchez, M, García-León, L D, Borbolla-Escoboza, J R
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens, Differentiation - metabolism
Cell Fractionation - methods
Dendritic Cells - pathology
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - administration & dosage
Hematopoietic Stem Cell Mobilization
Humans
Immune system
Immunology
Lymphocytes - pathology
Lymphoma, Non-Hodgkin - metabolism
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Male
Middle Aged
Multiple Myeloma - metabolism
Multiple Myeloma - pathology
Multiple Myeloma - therapy
Peripheral Blood Stem Cell Transplantation - methods
Recombinant Proteins
T cell receptors
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Between June 2003 and November 2004, we collected mobilized peripheral blood units from 29 patients with non-Hodgkin's lymphoma and multiple myeloma for autologous peripheral blood stem cell transplantation. They received granulocyte colony-stimulating factor (G-CSF) (16 micro g/kg/day) for a total of 5 days. Immediately before and 3 h after the fourth and fifth dose of G-CSF, we performed flow cytometry analysis to quantify: T cells (CD3+CD4+, CD3+CD8+), B cells (CD19+), NK cells (CD3-CD16+CD56+), NKT cells (CD3+CD16+CD56+), type 1 dendritic cells (DC1) (lin-HLA-DR+CD11c+), type 2 dendritic cells (DC2) (lin-HLA-DR+CD123+), regulatory T cells (Tregs) (CD4+CD25+), and activated T cells (CD3+HLA-DR+). All cell subsets were mobilized after G-CSF treatment with the exception of B, NK, and NKT lymphocytes. The median number of Treg cells before and after G-CSF was statistically different (29+/-14.9x10(6)/l vs 70.1+/-46.1x10(6)/l, P
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-006-0090-8